BRPI0417231A - método para qualificar estado da doença de chagas em um paciente, kit, produto do software, biomolécula purificada, e, métodos para qualificar estado da doença de chagas e para monitorar o curso de progressão da doença de chagas em um paciente - Google Patents

método para qualificar estado da doença de chagas em um paciente, kit, produto do software, biomolécula purificada, e, métodos para qualificar estado da doença de chagas e para monitorar o curso de progressão da doença de chagas em um paciente

Info

Publication number
BRPI0417231A
BRPI0417231A BRPI0417231-0A BRPI0417231A BRPI0417231A BR PI0417231 A BRPI0417231 A BR PI0417231A BR PI0417231 A BRPI0417231 A BR PI0417231A BR PI0417231 A BRPI0417231 A BR PI0417231A
Authority
BR
Brazil
Prior art keywords
chagas disease
patient
qualifying
disease status
progression
Prior art date
Application number
BRPI0417231-0A
Other languages
English (en)
Inventor
Momar Ndao
Brian Ward
Rebecca Caffrey
Terence Spithill
Hongashan Li
Vladimir Podust
Regis Perichon
Original Assignee
Ciphergen Biosystem Inc
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciphergen Biosystem Inc, Univ Mcgill filed Critical Ciphergen Biosystem Inc
Publication of BRPI0417231A publication Critical patent/BRPI0417231A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

"MéTODO PARA QUALIFICAR ESTADO DA DOENçA DE CHAGAS EM UM PACIENTE KIT, PRODUTO DO SOFTWARE, BIOMOLéCULA PURIFICADA, E, MéTODOS PARA QUALIFICAR ESTADO DA DOENçA DE CHAGAS E PARA MONITORAR O CURSO DE PROGRESSãO DA DOENçA DE CHAGAS EM UM PACIENTE". A presente invenção fornece biomarcadores com base em proteína e combinações de biomarcador que são úteis na qualificação do estado da doença de Chagas em um paciente. Em particular, os biomarcadores desta invenção são úteis para a classificação de uma amostra de paciente como infectada com doença de Chagas ou não infectado. Os biomarcadores podem ser detectados pela espectrometria de massa SELDI.
BRPI0417231-0A 2003-12-05 2004-12-06 método para qualificar estado da doença de chagas em um paciente, kit, produto do software, biomolécula purificada, e, métodos para qualificar estado da doença de chagas e para monitorar o curso de progressão da doença de chagas em um paciente BRPI0417231A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52715303P 2003-12-05 2003-12-05
US56509304P 2004-04-22 2004-04-22
US62551904P 2004-11-06 2004-11-06
PCT/US2004/040990 WO2005055812A2 (en) 2003-12-05 2004-12-06 Serum biomarkers for chagas disease

Publications (1)

Publication Number Publication Date
BRPI0417231A true BRPI0417231A (pt) 2007-04-17

Family

ID=34682161

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417231-0A BRPI0417231A (pt) 2003-12-05 2004-12-06 método para qualificar estado da doença de chagas em um paciente, kit, produto do software, biomolécula purificada, e, métodos para qualificar estado da doença de chagas e para monitorar o curso de progressão da doença de chagas em um paciente

Country Status (6)

Country Link
US (2) US8043825B2 (pt)
EP (1) EP1718763B1 (pt)
AT (1) ATE525478T1 (pt)
BR (1) BRPI0417231A (pt)
CA (1) CA2547861A1 (pt)
WO (1) WO2005055812A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007012052A1 (en) * 2005-07-20 2007-01-25 Medical College Of Georgia Research Institute Use of protein profiles in disease diagnosis and treatment
WO2007070809A2 (en) * 2005-12-12 2007-06-21 Mcgill University Biomarkers for babesia
WO2009059409A1 (en) * 2007-11-05 2009-05-14 The Royal Institution For The Advancement Of Learning/Mcgill University Biomarkers for visceral leishmaniasis
JP2009244154A (ja) * 2008-03-31 2009-10-22 Nationa Hospital Organization 老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法
US20110195488A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Devices for collection and stabilization of biomarkers in liquid samples
WO2015006752A1 (en) * 2013-07-12 2015-01-15 The Regents Of The University Of California Combination therapies for malaria
CN108393195B (zh) * 2018-02-06 2020-03-20 常州大学 一种湿法脱除pm2.5装置

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705751A (en) * 1983-12-28 1987-11-10 Wisconsin Alumni Research Foundation Process for preparation of multimeric plasma fibronectin
US5281522A (en) * 1988-09-15 1994-01-25 Adeza Biomedical Corporation Reagents and kits for determination of fetal fibronectin in a vaginal sample
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
EP0700521B1 (en) * 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
US5786156A (en) * 1993-12-21 1998-07-28 Perimmune Holdings, Inc. Immunoreactive peptides of APO(A)
US6107045A (en) * 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
ES2242191T3 (es) * 1994-09-14 2005-11-01 Baylor College Of Medicine Vacuna contra una infeccion por estreptococos del grupo a.
US6156546A (en) * 1997-05-16 2000-12-05 Washington State University Research Foundation Identification and molecular cloning of a gene encoding a fibronectin binding protein (CadF) from Campylobacter coli and Campylobacter jejuni
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
CA2309705A1 (en) 1998-02-16 1999-08-19 Dimas Tadeu Covas Serological diagnosis of chagas' disease
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
EP0976763B1 (en) * 1998-07-30 2003-11-05 Innogenetics N.V. Antigens and immunoassays for diagnosing Chagas' disease
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001031580A2 (en) 1999-10-27 2001-05-03 Biowulf Technologies, Llc Methods and devices for identifying patterns in biological systems
US20030078192A1 (en) * 2000-02-03 2003-04-24 Winter Gregory Paul Combinatorial protein domains
US6925389B2 (en) 2000-07-18 2005-08-02 Correlogic Systems, Inc., Process for discriminating between biological states based on hidden patterns from biological data
AU2002245043B2 (en) 2000-11-16 2006-10-26 Bio-Rad Laboratories, Inc. Method for analyzing mass spectra
US7299134B2 (en) * 2001-02-16 2007-11-20 Bio-Rad Laboratories, Inc. Method for correlating gene expression profiles with protein expression profiles
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US7179605B2 (en) * 2001-11-23 2007-02-20 Nanogen Inc. Fibronectin precursor biopolymer markers indicative of alzheimer's disease
US7094549B2 (en) * 2001-11-23 2006-08-22 Syn X Pharma, Inc. Fibronectin biopolymer marker indicative of insulin resistance
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
KR101107765B1 (ko) * 2002-08-06 2012-01-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암의 검출을 위한 생물 마커의 용도
MXPA05005073A (es) * 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
US7785782B2 (en) * 2002-12-12 2010-08-31 Novartis Vaccines And Diagnostics, Inc. Device and method for in-line blood testing using biochips
US8346482B2 (en) * 2003-08-22 2013-01-01 Fernandez Dennis S Integrated biosensor and simulation system for diagnosis and therapy
KR20070043868A (ko) * 2004-08-02 2007-04-25 칠드런'즈 메디컬 센터 코포레이션 암에 대한 혈소판 바이오마커

Also Published As

Publication number Publication date
EP1718763A4 (en) 2009-02-25
WO2005055812A3 (en) 2005-09-15
EP1718763B1 (en) 2011-09-21
US20120172356A1 (en) 2012-07-05
US20050260691A1 (en) 2005-11-24
US8043825B2 (en) 2011-10-25
WO2005055812A2 (en) 2005-06-23
EP1718763A2 (en) 2006-11-08
ATE525478T1 (de) 2011-10-15
CA2547861A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
IL251791B (en) Biomarker for ovarian cancer: ctap3-related proteins
CA2602088C (en) Biomarkers for ovarian cancer and endometrial cancer
WO2014037924A3 (en) Analysis of saliva proteome for biomarkers of gingivitis and periodontitis using ft-icr-ms/ms
EP4249605A3 (en) Methods for analyte detection
WO2007002535A3 (en) Biomarkers for ovarian cancer
WO2014201516A3 (en) Biomarker identification
WO2009083950A3 (en) Biomarkers for the prediction of renal injury
WO2007041245A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2013052505A3 (en) Methods and devices for assessing risk to a putative offspring of developing a condition
WO2013026026A3 (en) Shift correction for spectral analysis
ES2674177T3 (es) Preparación de suero
MX2009011494A (es) Marcadores de enfermedades.
WO2012164525A3 (en) Aging biomarkers
WO2007035766A3 (en) Biomarker for prostate cancer
EA201171178A1 (ru) Устройство и способ для определения и количественного анализа аналитов, в частности, микотоксинов
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
WO2006034032A3 (en) Biomarkers for breast cancer
BRPI0417231A (pt) método para qualificar estado da doença de chagas em um paciente, kit, produto do software, biomolécula purificada, e, métodos para qualificar estado da doença de chagas e para monitorar o curso de progressão da doença de chagas em um paciente
WO2007002527A3 (en) BIOMARKERS FOR OVARIAN CANCER: β-2 MICROGLOBULIN
WO2013076579A3 (en) Method for assessing risk of bone fracture
WO2006128082A3 (en) Biomarkers for breast cancer
BR112012024175A2 (pt) hbf e a1m como marcadores de estágio precoce para preeclampsia
WO2006085121A3 (en) Vgp peptide fragments as biomarkers for schizophrenic and bipolar disorders
WO2014184684A3 (en) Methods and biomarkers for detection of hematological cancers
WO2010043973A3 (en) Biomarkers for dengue

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE.